Trainings and Resources
16 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/19/2022
The U.S. Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), is announcing a State Opioid Response (SOR) grant funding opportunity that will provide nearly $1.5 billion to states and territories to help address the Nation’s opioid addiction and overdose epidemic. In President Biden’s State of the Union, he named beating the opioids epidemic as a pillar of his Unity Agenda. Today’s announcement is a critical step forward in that work, and the SOR program, along with the Tribal Opioid Response grant funding opportunity announced recently, are critical tools in President Biden’s inaugural National Drug Control Strategy released last month and the Health and Human Services’ (HHS) Overdose Prevention Strategy.
Posted 5/11/2022
The rate of drug overdose deaths in the USA has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance-related mortality. This study will address this gap.
Posted 3/16/2022
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database
Posted 9/22/2021 (updated 10/1/2021)
IMPORTANCE Polysubstance use is a concern for patients treated for opioid use disorder (OUD). While buprenorphine can curtail harmful opioid use, co-occurring use of nonprescribed substances, such as cocaine, methamphetamine, and other opioids, may negatively affect treatment outcomes.
OBJECTIVE To characterize factors associated with urine drug positivity for nonprescribed substances among patients prescribed buprenorphine
Posted 4/21/2021 (updated 9/2/2021)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 4/21/2021 (updated 9/2/2021)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 9/4/2020 (updated 9/2/2021)
The analysis examined syndromic surveillance data from 2018–2019 in 29 states for suspected nonfatal drug and polydrug overdoses treated in emergency departments.
Posted 9/1/2020 (updated 9/2/2021)
The National Harm Reduction Coalition is thrilled to announce our new name, new look, and new website! The Harm Reduction movement has changed over the course of 25 years and so has our organization. More than 900,000 people access the resources on harmreduction.org each year. Our website is a valuable resource to people who use drugs and their loved ones, harm reduction programs, public health departments, health care workers, researchers, students, and drug treatment providers across the country.
Posted 8/24/2020 (updated 9/2/2021)
Lessons Learned From Listening Sessions With Five Tribes in Minnesota.
Posted 8/18/2020 (updated 9/2/2021)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.